Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome

Bianca M M Streng; Marin Bont; Eveline M Delemarre; Rob S Binnendijk; Gaby Smit; Gerco den Hartog; Antonia M W Coppus; Esther de Vries; Michel E Weijerman; Regina Lamberts; Gert de Graaf; Fiona R van der Klis; Gestur Vidarsson; Neele Rave; Louis J Bont; Joanne G Wildenbeest

doi:10.1093/infdis/jiac235

Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome

J Infect Dis. 2022 Sep 4;226(4):673-677. doi: 10.1093/infdis/jiac235.

Authors

Bianca M M Streng¹, Marin Bont¹, Eveline M Delemarre^{1

2}, Rob S Binnendijk³, Gaby Smit³, Gerco den Hartog³, Antonia M W Coppus⁴, Esther de Vries^{5

6}, Michel E Weijerman⁷, Regina Lamberts⁷, Gert de Graaf⁸, Fiona R van der Klis³, Gestur Vidarsson^{9

10}, Neele Rave¹, Louis J Bont¹, Joanne G Wildenbeest¹

Affiliations

¹ Department of Paediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.
² Center of Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
³ Laboratory for Vaccine-Preventable Diseases, National Institute of Public Health and the Environment, Bilthoven, The Netherlands.
⁴ Department for Primary and Community Care, Radboud University Medical Center, Nijmegen, The Netherlands.
⁵ Tranzo, Tilburg School of Social and Behavioral Sciences, Tilburg University, Tilburg, The Netherlands.
⁶ Jeroen Bosch Academy Research, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands.
⁷ Department of Pediatrics, Alrijne Hospital, Leiderdorp, The Netherlands.
⁸ Foundation Stichting Down Syndroom, Meppel, The Netherlands.
⁹ Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
¹⁰ Department of Biomolecular Mass Spectrometry and Proteomics, Utrecht Institute for Pharmaceutical Sciences and Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, The Netherlands.

Abstract

The risk of a severe course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in adults with Down syndrome is increased, resulting in an up to 10-fold increase in mortality, in particular in those >40 years of age. After primary SARS-CoV-2 vaccination, the higher risks remain. In this prospective observational cohort study, SARS-CoV-2 spike S1-specific antibody responses after routine SARS-CoV-2 vaccination (BNT162b2, messenger RNA [mRNA]-1273, or ChAdOx1) in adults with Down syndrome and healthy controls were compared. Adults with Down syndrome showed lower antibody concentrations after 2 mRNA vaccinations or after 2 ChAdOx1 vaccinations. After 2 mRNA vaccinations, lower antibody concentrations were seen with increasing age.

Clinical trials registration: NCT05145348.

Keywords: COVID-19 vaccination; Down syndrome; SARS-CoV-2; antibody response.

Publication types

Observational Study
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antibodies, Viral
Antibody Formation
BNT162 Vaccine
COVID-19 Vaccines
COVID-19* / prevention & control
Down Syndrome*
Humans
Prospective Studies
RNA, Messenger
SARS-CoV-2
Vaccination

Substances

Antibodies, Viral
COVID-19 Vaccines
RNA, Messenger
BNT162 Vaccine

Associated data

ClinicalTrials.gov/NCT05145348